Department of Clinical Sciences, Pediatrics, Umeå University, Sweden.
Pediatr Infect Dis J. 2011 Sep;30(9):e155-63. doi: 10.1097/INF.0b013e31821feeb7.
Immunogenicity of 10-valent pneumococcal nontypeable Haemophilus influenzae protein d conjugate vaccine (PHiD-CV), administered as 2-dose or 3-dose priming followed by a booster dose, has been described previously. The present study evaluated immunologic memory following PHiD-CV vaccination according to these vaccination schedules.
A dose of PHiD-CV (to test anamnestic responses) was administered to 172 children at 36 to 46 months of age; 110 of them had previously been vaccinated with PHiD-CV according to 2 + 1 or 3 + 1 schedules (PHiD-CV [2 + 1] and PHiD-CV [3 + 1] groups) and 62 were unprimed age-matched controls. To measure immune responses before and 7 to 10 days after the PHiD-CV dose, 22F-inhibition enzyme-linked immunosorbent assay and opsonophagocytic activity (OPA) assay were used.
Serotype-specific IgG geometric mean concentrations (GMCs) and OPA geometric mean titers increased substantially (from before to 7 to 10 days after the additional PHiD-CV dose) for all 10 vaccines and 2 cross-reactive serotypes (6A and 19A) in the children previously vaccinated with PHiD-CV, regardless of the vaccination schedule used. Antibody GMCs and OPA geometric mean titers after the administration of the PHiD-CV dose were markedly higher in both previously PHiD-CV-vaccinated groups than in the unprimed control group, clearly demonstrating prior induction of immunologic memory. Antiprotein D antibody GMCs had also increased substantially from before to 7 to 10 days after vaccination in all 3 groups, with higher antibody GMCs in the previously vaccinated groups than in the control group.
PHiD-CV vaccination according to 2 + 1 or 3 + 1 schedules resulted in comparable anamnestic immune responses. These findings suggest that similar protective efficacy may be achieved with both the schedules.
此前已经描述过，10 价肺炎球菌/无荚膜流感嗜血杆菌蛋白 D 结合疫苗（PHiD-CV）作为两剂或三剂初免序贯加强一剂的免疫原性。本研究根据这些免疫接种方案评估了 PHiD-CV 接种后的免疫记忆。
172 名 36 至 46 月龄的儿童接种了一剂 PHiD-CV（用于检测记忆应答）；其中 110 名儿童之前按照 2+1 或 3+1 方案（PHiD-CV[2+1]和 PHiD-CV[3+1]组）接种了 PHiD-CV，62 名是未接种的年龄匹配对照。为了在接种 PHiD-CV 前和接种后 7 至 10 天测量免疫反应，使用 22F 抑制酶联免疫吸附试验和调理吞噬活性（OPA）试验。
在之前接种过 PHiD-CV 的儿童中，所有 10 种疫苗和 2 种交叉反应性血清型（6A 和 19A）的血清型特异性 IgG 几何平均浓度（GMC）和 OPA 几何平均滴度在接种额外的 PHiD-CV 后都有显著增加（与接种前相比），与使用的免疫接种方案无关。在之前接种过 PHiD-CV 的两组中，接种 PHiD-CV 后，抗体 GMC 和 OPA 几何平均滴度均明显高于未接种的对照组，清楚地表明了免疫记忆的预先诱导。在所有 3 组中，接种后第 7 至 10 天，抗蛋白 D 抗体 GMC 也显著增加，与对照组相比，之前接种过的组抗体 GMC 更高。
按照 2+1 或 3+1 方案接种 PHiD-CV 可产生相似的记忆免疫应答。这些发现表明，这两种方案可能具有相似的保护效力。
